HealthcareServices

Cholestatic Pruritus Sector Forecast Shows Robust Momentum, Climbing to $25.98 Billion With 5.1% CAGR

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cholestatic pruritus market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Cholestatic Pruritus Market in 2026, and what figure is it projected to hit by 2030?

The cholestatic pruritus market has experienced substantial expansion in recent years. Projections indicate it will expand from $20.22 billion in 2025 to $21.3 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. Historically, this growth is linked to factors such as increasing prevalence of chronic liver diseases, limited effectiveness of traditional antihistamines, growth of hepatology specialty care, rising diagnosis of cholestatic disorders, and expansion of supportive care treatments.

The cholestatic pruritus market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $25.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%.

This projected growth during the forecast period is driven by several factors, including the increasing number of approvals for new therapeutic agents, a heightened emphasis on improving patients’ quality of life, the wider availability of targeted drugs for liver diseases, expanding investments in research for rare conditions, and the growing implementation of personalized treatment approaches.

Key developments anticipated within this forecast timeframe encompass the intensified creation of targeted anti-pruritic treatments, a stronger emphasis on treatment strategies specific to symptoms, the increased utilization of oral bile acid modulators, an expansion of research endeavors in liver disease management, and the implementation of improved patient-centered care models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp

Which Drivers Are Affecting Market Participation In The Cholestatic Pruritus Market?

The rising prevalence of liver diseases is projected to spur the expansion of the cholestatic pruritus market moving forward. Liver diseases represent a diverse group of conditions that impair liver function, covering infections, autoimmune disorders, genetic conditions, and damage from toxins, often leading to inflammation, scarring, or liver failure. The increasing occurrence of liver diseases is exacerbated by factors such as growing obesity, diabetes, alcohol consumption, viral hepatitis infections, and exposure to toxins and environmental elements. Cholestatic pruritus plays a role in the detection and management of liver diseases by acting as a critical symptom indicating compromised bile flow, which frequently necessitates further investigation and treatment of underlying hepatic conditions. For instance, in 2023, according to the Office for Health Improvement and Disparities (OHID), a UK-Based government agency, England recorded 85,665 hospital admissions for liver disease during the financial year ending in 2023. Hence, the increasing incidence of liver diseases will propel the growth of the cholestatic pruritus market.

What Segment Categories Are Covered In The Cholestatic Pruritus Market?

The cholestatic pruritus market covered in this report is segmented –

1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis Of Pregnancy (ICP), Other Disease Types

2) By Treatment Type: Medications, Phototherapy, Other Treatment Types

3) By Route Of Administration: Oral, Topical, Injectable

4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare

Subsegments:

1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure

2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures

3) By Intrahepatic Cholestasis Of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk

4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders

Which Trends Are Shaping Activity Within The Cholestatic Pruritus Market?

Major companies operating in the cholestatic pruritus market are focusing on developing innovative solutions, such as oral solutions, to manage symptoms more effectively, improve patient compliance, and provide targeted relief by addressing the underlying causes of bile salt accumulation and inflammation. An oral solution for the treatment of cholestatic pruritus refers to a liquid medication formulation designed to reduce bile acid accumulation and alleviate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution. This approval is for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered ileal bile acid transporter inhibitor holds a breakthrough therapy designation for PFIC type 2. LIVMARLI is anticipated to make a significant impact on patients with cholestatic pruritus linked to PFIC, offering a much-needed treatment option for those with the rarest subtypes.

Which Major Industry Participants Are Leading The Cholestatic Pruritus Market Growth?

Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, ProQR Therapeutics NV.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report

Which Region Is Projected To Lead The Cholestatic Pruritus Market During The Forecast Period?

North America was the largest region in the cholestatic pruritus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cholestatic Pruritus Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21140&type=smp

Browse Through More Reports Similar to the Global Cholestatic Pruritus Market 2026, By The Business Research Company

Hidradenitis Suppurativa Market Report 2026

https://www.thebusinessresearchcompany.com/report/hidradenitis-suppurativa-global-market-report

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pompe Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795